Heatwurx (NASDAQ:PCSA) Upgraded to “Hold” at Wall Street Zen
by Danessa Lincoln · The Markets DailyWall Street Zen upgraded shares of Heatwurx (NASDAQ:PCSA – Free Report) from a sell rating to a hold rating in a research report released on Saturday morning.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Heatwurx in a research report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $25.00.
Read Our Latest Stock Analysis on PCSA
Heatwurx Stock Up 1.7%
Shares of PCSA opened at $2.93 on Friday. The firm’s 50 day moving average price is $6.29 and its 200 day moving average price is $6.06. The company has a market cap of $6.65 million, a P/E ratio of -0.09 and a beta of 1.13. Heatwurx has a fifty-two week low of $2.74 and a fifty-two week high of $27.00.
Heatwurx (NASDAQ:PCSA – Get Free Report) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.00) by $0.25. Research analysts forecast that Heatwurx will post -4.05 earnings per share for the current year.
About Heatwurx
Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.